TMEM221: A Drug Target / Disease Biomarker (G100130519)

Target Name: TMEM221

NCBI ID: G100130519

TMEM221

Other Name(s): TM221_HUMAN | Transmembrane protein 221 isoform X1 | transmembrane protein 221 | Putative transmembrane protein ENSP00000342162 | Transmembrane protein 221

TMEM221: A Drug Target / Disease Biomarker

TMEM221 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the transmembrane protein family, which means that it is involved in the formation of the boundary between the cell membrane and the surrounding tissue. TMEM221 is also known as AQP1, and it is characterized by the presence of a unique N-terminal transmembrane domain and a C-terminal extracellular domain.

The N-terminal transmembrane domain of TMEM221 is composed of a unique amino acid sequence that is involved in the formation of the protein's transmembrane region. This region is thought to play a role in the regulation of various physiological processes that are dependent on the proper functioning of the cell membrane. The C-terminal extracellular domain of TMEM221 is composed of a unique amino acid sequence that is involved in the regulation of various cellular processes that are dependent on the proper functioning of the cell membrane.

TMEM221 is a protein that has been shown to play a role in a variety of physiological processes that are dependent on the proper functioning of the cell membrane. For example, studies have shown that TMEM221 is involved in the regulation of the growth and development of various tissues, including the brain and the heart. TMEM221 has also been shown to play a role in the regulation of various cellular processes that are dependent on the proper functioning of the cell membrane, including the regulation of ion and water transport, as well as the regulation of signaling pathways that are involved in cellular processes.

In addition to its role in the regulation of cellular processes, TMEM221 is also thought to play a role in the regulation of the structure and function of the cell membrane itself. This is because of the unique amino acid sequence that is present in the N-terminal transmembrane domain of the protein. This sequence is thought to play a role in the formation of the protein's transmembrane region, and this region is involved in the regulation of various physiological processes that are dependent on the proper functioning of the cell membrane.

Because of its role in the regulation of various physiological processes that are dependent on the proper functioning of the cell membrane, TMEM221 is thought to be a potential drug target or biomarker. Researchers are currently working to develop compounds that can inhibit the activity of TMEM221 and to understand its role in the regulation of cellular processes. These efforts are likely to lead to the development of new treatments for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

Overall, TMEM221 is a protein that is involved in the regulation of various physiological processes that are dependent on the proper functioning of the cell membrane. Its unique N-terminal transmembrane domain and C-terminal extracellular domain, as well as its role in the regulation of cellular processes that are dependent on the proper functioning of the cell membrane, make it a promising candidate for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of TMEM221 in the regulation of cellular processes and to develop effective treatments for the diseases that are dependent on its function.

Protein Name: Transmembrane Protein 221

The "TMEM221 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM221 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets